Fatal hyperammonemia in a patient with systemic lupus erythematosus

Internal Medicine

Volumn 37, Issue 8, 1998, Pages 700-703

  Ichikawa, Haruo ^a   Amano, Tetsuki ^a   Kawabata, Kenji ^a   Kushiro, Masahiko ^a   Wada, Jun ^a   Nagake, Yoshio ^a   Making, Hirofumi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Aspirin; Cimetidine; Hemodialysis; Hyperammonemic encephalopathy; Valproic acid (VPA)

Indexed keywords

ACETYLSALICYLIC ACID; AMMONIA; BENZOIC ACID; CARNITINE; CIMETIDINE; CREATININE; METHYLPREDNISOLONE; PREDNISOLONE; VALPROIC ACID;

ADULT; AMINO ACID BLOOD LEVEL; AMMONIA BLOOD LEVEL; ARTICLE; CASE REPORT; FATALITY; FEMALE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYPERAMMONEMIA; HYPOALBUMINEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; METABOLIC ENCEPHALOPATHY; NEPHROTIC SYNDROME; ORAL DRUG ADMINISTRATION; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0031686341     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.37.700     Document Type: Article

References (16)

1. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271, 1982.
2. Tizianello A, De Ferrari G, Garibotto G, Robaudo C. Amino acid metabolism and the liver in renal failure. Am J Clin Nutr 33: 1354, 1980.
3. Agroyannis B, Tzanatos H, Chondros K, et al. Evaluation of blood ammonia alterations in uremic patients under hemodialysis and CAPD. Int J Artif Organs 17: 307, 1994 (letter).
4. Coulter DL, Allen RJ. Secondary hyperammonaemia: A possible mechanism for valproate encephalopathy. Lancet 1: 1310, 1980 (letter).
5. Watson AJ, Chambers T, Karp JE, Risch VR, Walker WG, Brusilow SW. Transient idiopathic hyperammonaemia in adults. Lancet 2: 1271, 1985.
6. Pimentel JL Jr, Brusilow SW, Mitch WE. Unexpected encephalopathy in chronic renal failure: Hyperammonemia complicating acute peritonitis. J Am Soc Nephrol 5: 1066, 1994.
7. Zaret BS, Beckner RR, Marini AM, Wagle W, Passarelli C. Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction. Neurology 32: 206, 1982.
8. Coulter DL, Allen RJ. Hyperammonemia with valproic acid therapy. J Pediatr 99: 317, 1981.
9. Marini AM, Zaret BS, Beckner RR. Hepatic and renal contributions to valproic acid induced hyperammonemia. Neurology 38: 365, 1988.
10. Gal P, Oles KS, Gilman JT, Weaver R. Valproic acid efficacy, toxicity and pharmacokinetics in neonates with intractable seizures. Neurology 38: 467, 1988.
11. Gaskins JD, Holt RJ, Postelnick M. Nondosage-dependent valproic acid-induced hyperammonemia and coma. Clin Pharm 3: 313, 1984.
12. Coulter DL. Carnitine deficiency: A possible mechanism for valproate hepatotoxicity. Lancet i: 689, 1984 (letter).
13. Murphy JV, Marquardt KM, Shug AL. Valproic acid associated abnormalities of carnitine metabolism. Lancet i: 820, 1985 (letter).
14. Roodhooft AM, Van Dam K, Haentjens D, Verpooten GA, Van Acker KJ. Acute sodium valproate intoxication: occurrence of renal failure and treatment with haemoperfusion-hemodialysis. Eur J Pediatr 149: 363, 1990.
15. Orr JM, Abbott FS, Farrell K, Ferguson S, Sheppard I, Godolphin W. Interaction between valproic acid and aspirin in epileptic children: Serum protein binding and metabolic effects. Clin Pharmacol Ther 31: 642, 1982.
16. Webster LK, Mihaly GW, Jones DB, Smallwood RA, Phillips JA, Vajda FJ. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur J Clin Pharmacol 27: 341, 1984.